Isigulana sokuqala esinokulahlekelwa kokuva okunxulumene neminyaka sifumana unyango olutsha

I-ACU085 isetyenziswe kwisigulane sokuqala esinokulahleka kokuva okunxulumene neminyaka (presbycusis) kwiSigaba se-1b sophononongo lweklinikhi eJamani. Uvavanyo lwangaphambili lwezigulane oluhambelana nemigaqo ebanzi/yokukhutshwa kulingo oluqhubekayo sele luza kugqitywa. Ukongeza kwinjongo engundoqo yophononongo, uvavanyo lokhuseleko kunye nokunyamezeleka komgqatswa wechiza ebantwini okokuqala, uluhlu olubanzi lweemvavanyo zokumamela ezizimeleyo kunye nenjongo ziyaqhutywa ukuxhasa uphando lothethathethwano ekujoliswe kulo.

I-ACU085 yi-proprietary encinci ye-molecule, umviwa we-otoprotective yeziyobisi ohlengahlengisa i-molecular target echazwe kakuhle ngokukhethwayo kwiiseli zeemvakalelo zendlebe yangaphakathi, ebizwa ngokuba ziiseli zeenwele zangaphandle (OHC). I-ACU085 ibonakaliswe yimowudi yezenzo ezimbini ezizodwa: i-molecule ibangela ukuphuculwa okubukhali komsebenzi wokuva kwaye inikezela ngokugcinwa kwexesha elide kwii-OHCs ezingapheliyo. NgoDisemba ka-2021, i-Acousia Therapeutics yanikwa i-CTA yi-BfArM yaseJamani ukuba iqalise ulingo lwayo lwezonyango lokuqala kwiSigaba 1b somntu se-ACU085.

"Eli nyathelo elilandelayo le-Acousia's otoprotective drug candidate ACOU085 kwizifundo kwizigulane eziphethwe yi-presbycusis ibonisa isiganeko esibalulekileyo kwindlela yethu yokwenza ukulahlekelwa kwindlebe kube sisifo esinyangekayo," kusho uDkt Tim Boelke, iGosa eliyiNtloko yeSigqeba kunye neGosa eliyiNtloko lezoNyango zenkampani.

"Ndiyazingca kakhulu ukuba umsebenzi wethu oqhutywa yi-hypothesis, umsebenzi wesayensi ngoku uhambela kwinqanaba lezonyango kuphela iminyaka emi-6 emva kokuqalisa inkqubo yophuhliso lweziyobisi kwinoveli, ekujoliswe kuyo kweziyobisi," wongeza uHubert Löwenheim, uNjingalwazi kunye noNjingalwazi. USihlalo weSebe le-Otolaryngology-iNtloko kunye noNyango lweNgxoxo yeYunivesithi yaseTübingen kunye ne-Acousia Therapeutics co-founder.